KONECT RESILIA Aortic Valved Conduit (AVC) Real-world Study Assessing Safety and Performance (KONECTION)
KONECTION is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in up to 250 participants who will receive the KONECT RESILIA aortic valved conduit, Model 11060A.
研究概览
详细说明
Subjects in the KONECTION study will be enrolled at up to 20 sites in Europe and Canada. The population will be participants requiring replacement of their diseased native or prosthetic aortic valve, and the associated repair or replacement of a damaged or diseased ascending aorta.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Sabrina Hundt, PhD
- 电话号码:+49 (0)151 67550601
- 邮箱:Sabrina_Hundt@edwards.com
学习地点
-
-
-
Berlin、德国、13353
- 招聘中
- Deutsches Herzzentrum der Charité
-
首席研究员:
- Herko Grubitzsch, PD Dr. med.
-
-
Bavaria
-
München、Bavaria、德国、80636
- 招聘中
- TUM Klinikum Deutsches Herzzentrum
-
首席研究员:
- Markus Krane, Prof. Dr. med.
-
-
North Rhine-Westphalia
-
Bonn、North Rhine-Westphalia、德国、53127
- 招聘中
- Universitätsklinikum Bonn
-
首席研究员:
- Farhad Bakhtiary, Prof. Dr. med.
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
The target population includes adult candidates who require replacement of their native or prosthetic aortic valve, and the associated repair or replacement of a damaged or diseased ascending aorta.
描述
Inclusion Criteria:
- 18 years or older at the time of informed consent
- Have a diseased native or prosthetic aortic valve and a damaged or diseased ascending aorta that requires aortic valved conduit replacement surgery with the KONECT RESILIA AVC
- Provide written informed consent
- Willing to follow protocol requirements
Exclusion Criteria:
- Active endocarditis or endocarditis within 3 months prior to the study index procedure
- Emergency procedure
- Stage 4 renal disease (estimated glomerular filtration rate [eGFR] <30 excluded) or requiring dialysis
- Less than 2-year life expectancy due to non-cardiovascular life-threatening disease in the opinion of the study investigator
- High predicted risk of mortality prior to the procedure: Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) ≥8%
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Edwards KONECT RESILIA AVC
Subjects who were treated with the Edwards KONECT RESILIA AVC |
Surgical replacement of the aortic valve and ascending aorta with the Edwards KONECT RESILIA AVC |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of participant's freedom from death and/or device related reintervention
大体时间:≤ 30 days
|
Participants' freedom from valve-related death or valve- and/or graft-related reintervention. Time to events were estimated by Kaplan-Meier method. |
≤ 30 days
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Participant's linearized rate of thromboembolism
大体时间:Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Participant's linearized rate of valve thrombosis
大体时间:Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Participant's linearized rate of major paravalvular leak
大体时间:Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Participant's linearized rate of endocarditis
大体时间:Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Participant's linearized rate of major hemorrhage
大体时间:Events occurring ≥ 31 days and up through 5 years post-implant
|
A linearized rate percentage is calculated by the following equation: [(Total number of late adverse events in each category/total number of late patient years) x 100]. Late adverse events are events that occur ≥ 31 days post-implant through each subject's last follow-up visit or contact. Late patient years are calculated by totaling the amount of time the valve is implanted in the patient while participating in the trial and the count begins at ≥ 31 days post-implant through all subject's last follow-up visit or contact. |
Events occurring ≥ 31 days and up through 5 years post-implant
|
|
Percentage of participant's with freedom from death and/or device related reintervention
大体时间:1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up
|
Participants' freedom from valve-related death or valve- and/or graft-related reintervention. Time to events were estimated by Kaplan-Meier method. |
1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up
|
|
Participant's functional improvement over time from baseline for New York Heart Association (NYHA) Class
大体时间:Baseline, 1 month, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up
|
The New York Heart Association functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity. Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or anginal syndrome may be present even at rest. |
Baseline, 1 month, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, and 10- Years follow-up
|
|
Participant's average mean gradient measurement over time
大体时间:1 month, 1-, 3-, and 5- Years follow-up
|
Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve. |
1 month, 1-, 3-, and 5- Years follow-up
|
|
Participant's average peak gradient measurement over time
大体时间:1 month, 1-, 3-, and 5- Years follow-up
|
Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve. |
1 month, 1-, 3-, and 5- Years follow-up
|
|
Participant's average Effective Orifice Area (EOA) measurement over time
大体时间:1 month, 1-, 3-, and 5- Years follow-up
|
Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve. |
1 month, 1-, 3-, and 5- Years follow-up
|
|
Participant's average Effective Orifice Area Index (EOAI) measurement over time
大体时间:1 month, 1-, 3-, and 5- Years follow-up
|
Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the aortic valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient and the size and type of valve. |
1 month, 1-, 3-, and 5- Years follow-up
|
合作者和调查者
调查人员
- 首席研究员:Markus Krane, Prof. Dr. med.、TUM Universitätsklinikum Deutsches Herzzentrum
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.